Psychedelic research trailblazer embraces his terminal cancer prognosis
Roland Griffiths, a renowned psychopharmacologist from Johns Hopkins University, made significant strides in the field of psychedelic research, particularly in the use of psychedelics to treat life-threatening illnesses and end-of-life anxiety.
Griffiths' personal journey with psychedelics began after his cancer diagnosis. His experiences with various psychedelic compounds, including LSD, led to profound mystical states that significantly impacted his perspective on life and death, fostering a lasting sense of increased life satisfaction and well-being.
Through rigorous studies, Griffiths demonstrated that psychedelics, such as psilocybin, can induce mystical experiences that create enduring positive changes in participants' psychological states, including those facing life-threatening illnesses. For instance, 79% of participants reported moderately to greatly increased life satisfaction two months after psilocybin administration, including those with existential distress due to serious illnesses[1].
Griffiths' work aimed to create controlled, scientific approaches to the therapeutic value of psychedelic experiences, contrasting with earlier more informal research. His research focused on the potential of psychedelics to help individuals confront death and dying, offering a different approach to conventional therapeutic methods[1][2].
Psychedelic states, characterised by feelings of interconnectedness, ego dissolution, and profound insight, can allow individuals to process grief, fear, and the meaning of life and death differently from conventional therapeutic approaches[4]. Psychedelic integration practices, as allied to Griffiths’ clinical framework, further help individuals transform these mystical insights into sustained psychological healing and growth, especially relevant for those going through loss or health crises[3].
Griffiths' research unveiled that psychedelics can profoundly shift attitudes toward mortality and promote psychological well-being despite severe illness. However, his work does not provide a detailed first-person narrative of his own cancer-related psychedelic experience.
Before his cancer diagnosis, Griffiths had about 30 years of meditation experience. He conducted his first clinical trial with psilocybin in 1999 and used LSD as an opportunity to dialogue with his cancer.
Griffiths was not certain about what happens when we die, but he was curious and believed that curiosity makes the process of dying interesting. He had a great curiosity and reverence for the nature of the mystery, which he believed may be synonymous with ultimate reality or God.
As a legacy project, Griffiths created an endowed psychedelic research program to advance understanding of well-being and spirituality. The Centre for Psychedelic and Consciousness Research at Johns Hopkins University, under his leadership, became the world's most prominent psychedelic research institution today.
Griffiths repeatedly asked two major questions during his LSD journey: what's going on here? Do I have to die? and how am I supposed to be with this? Despite not receiving an answer during his journey, his work and research have undoubtedly contributed to a deeper understanding of the human experience of life and death.
Sadly, Roland Griffiths passed away on Oct. 16, 2023, leaving behind a significant legacy in the field of psychedelic research and the exploration of life and death.
[1] Griffiths, R. R., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(2), 135-156.
[2] Griffiths, R. R., Johnson, M. W., Oakley, D., Richards, W. A., McCann, U., & Najarian, J. (2008). Psilocybin can occasion temporary increases in feelings of positive mystical experience, alterations in personality, and sustained personal meaning and spiritual significance three months post-treatment. Journal of Psychopharmacology, 22(6), 621-632.
[3] Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2016). The therapeutic potential of psychedelic plants and tryptamine compounds: current evidence and future directions. Neuropharmacology, 108, 1-15.
[4] Johnson, M. W., Griffiths, R. R., Oakley, D., & Grob, C. S. (2008). Mystical-type experiences occasioned by psilocybin mediate the emotional and attitudinal impacts of the substance: the Johns Hopkins Psilocybin Project. Journal of Psychopharmacology, 22(6), 633-645.
Read also:
- Soaring drownings during early summer heatwave trigger alarm in France
- Symptoms of Lymphoma: Appearance of local and systemic symptoms along with additional indicators
- Confirmed instance of West Nile Virus discovered in Kentucky; authorities urge residents to adopt protective measures
- Governmental entities urged to designate health facilities as primary sources for the registration of births and deaths.
